Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ MYOZ2 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA576946
Description
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
The calcineurin-binding protein Myozenin 2, also designated calsarcin-1, is a member of the calsarcin protein family. Calcineurin is a calcium- and calmodulin-dependent protein phosphatase that is involved in controlling the slow fiber gene expression in skeletal muscle and hypertrophy of cardiac muscle. The calsarcins are sarcomeric proteins that couple calcineurin and muscle activity. In cardiac and skeletal muscle cells, Myozenin 2 binds calcineurin to α-actinin at the Z-line of the sarcomere. During embryogenesis, Myozenin 1 and 2 are expressed in developing muscle. The Myozenin 2 gene maps to chromosome 4q and is expressed specifically in adult cardiac and slow-twitch skeletal muscle, while Myozenin 1 is only detected in fast skeletal muscle.
Specifications
MYOZ2 | |
Polyclonal | |
Unconjugated | |
MYOZ2 | |
1110012I24Rik; C4orf5; calcineurin-binding protein calsarcin-1; calsarcin-1; CMH16; CS-1; Fatz-2; FATZ-related protein 2; muscle-specific protein; myoz2; myozenin 2; myozenin-2; myozenin-like 2; Myozl2 | |
Rabbit | |
Antigen affinity chromatography | |
RUO | |
295426, 51778, 59006 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Western Blot, Immunocytochemistry | |
1 mg/mL | |
PBS with 50% glycerol and 0.02% sodium azide; pH 7.2 | |
Q9JJW5, Q9NPC6 | |
MYOZ2 | |
Recombinant full length Human MYOZ2. | |
100 μL | |
Primary | |
Human, Mouse, Rat | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction